Asterand Receives Contract Extension From NCI (6575R)
November 08 2011 - 2:01AM
UK Regulatory
TIDMATD
RNS Number : 6575R
Asterand PLC
08 November 2011
For Immediate Release 8 November 2011
Asterand plc
Asterand Receives Contract Extension From NCI
Asterand plc ("Asterand" or the "Company" - LSE: ATD) announces
today that, further to the announcement on 23 September 2011, it
has received notification from the National Cancer Institute
("NCI") that it will grant the Company a no cost contract extension
to 30 September 2014 for The Cancer Genome Atlas contract ("TCGA").
This extension will allow Asterand to realise unexpended funds for
the initial $5.4m contract beyond the original expiration date of
23 February 2012.
Contacts:
Asterand plc
Jack Davis, Chairman and Interim Chief Tel: + 44 (0) 1763 211 600 / +
Executive Officer 1 (313) 263-0960
Alan Fishman, Interim Chief Financial As above
Officer
Buchanan Communications
Lisa Baderoon / Mark Court / Isabel Tel: +44 (0) 20 7466 5000
Podda
Daniel Stewart & Company plc
Antony Legge Tel: +44 (0) 20 7776 6550
Martin Lampshire
About Asterand
Asterand plc is a leading supplier of high quality human tissue
and tissue-based services. Our comprehensive approach to human
tissue and research services offers pharmaceutical, biotech and
diagnostic companies the unique opportunity to have one company
meet all of their human biomaterial needs along the continuum of
drug discovery and development. Our mission is to accelerate target
discovery and compound validation and enable pharmaceutical and
biotechnology companies to take safer and more effective drugs into
the market. For more information about Asterand, go to
www.asterand.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZMMGMZNRGMZZ
Bioseek (LSE:ATD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioseek (LSE:ATD)
Historical Stock Chart
From Jul 2023 to Jul 2024